Qingfeng Pharmaceutical Group will attend “The 43rd Annual J.P. Morgan Healthcare Conference” in San Francisco, from January 13-16, 2025. Qingfeng would like to hold one-on-one meetings ...
On June 28, the Eribulin Mesilate Injection developed by Qingfeng Pharmaceutical Group was approved for marketing by the U.S. Food and Drug Administration (FDA), making Qingfeng Pharmaceutical the ...
On June 28, the Brivaracetam tablets (trade name: Qingruitan®) developed by Qingfeng Pharmaceutical Group were officially approved for marketing by the National Medical Products Administration. The...